Antacids, such as proton pump inhibitors and histamine H2-receptor antagonists, have been found to reduce the risk of GER-associated pulmonary damages (Raghu et al., 2006; Lee et al., 2011). Here, HRH2 is linked to gastroesophageal reflux disease.